Phase 2 Combination Study With Escalating Doses of MS1819-SD on Top of a Stable Dose of PPEs
NCT04302662
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Cystic Fibrosis
Cystic Fibrosis Gastrointestinal Disease
Cystic Fibrosis of Pancreas
Interventions
DRUG:
MS1819-SD
Sponsor
AzurRx SAS